Last updated on March 2019

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)


Brief description of study

This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult patients for the prevention of ECH.

Clinical Study Identifier: NCT02945046

Contact Investigators or Research Sites near you

Start Over

Teva Investigational Site 78122

Parkville, Australia
1.71miles
  Connect »

Teva Investigational Site 78123

Melbourne, Australia
3.3miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.